Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical leader advancing novel therapies for chronic hepatitis B through RNA interference and lipid nanoparticle delivery systems. This page provides investors and industry observers with timely updates on the company’s scientific progress, regulatory milestones, and strategic partnerships.
Access consolidated news coverage of ABUS’s clinical trials, patent developments, and collaborative research initiatives. Our repository includes press releases on drug candidate advancements, financial disclosures, and peer-reviewed study outcomes – all essential for tracking this innovator’s pursuit of HBV functional cures.
Key updates cover three critical areas: clinical-stage developments targeting viral suppression, technology licensing agreements leveraging proprietary LNP platforms, and research publications validating therapeutic approaches. Regular monitoring ensures you stay informed about ABUS’s role in reshaping infectious disease treatment paradigms.
Bookmark this page for direct access to verified updates from Arbutus Biopharma and third-party analyses. Check back frequently to track how ABUS’s dual focus on antiviral therapies and delivery technologies positions it within the competitive biopharmaceutical landscape.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its Q1 2021 results, showcasing advancements in its HBV pipeline, particularly with AB-729 and AB-836. AB-729 has shown significant declines in hepatitis B surface antigen levels with promising safety profiles. The company commenced a Phase 2 clinical trial for a combination regimen involving AB-729 and other treatments for chronic HBV. Financially, Arbutus ended Q1 with $132 million in cash but recorded a net loss of $19.6 million. The firm anticipates significant data releases and trial advancements in the coming quarters.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its first quarter 2021 financial results and corporate update scheduled for May 5, 2021. Key details include the release of the financial results at 7:30 a.m. ET followed by a conference call/webcast at 8:45 a.m. ET. The domestic dial-in number for the call is (866) 393-1607, and international callers can reach (914) 495-8556 with conference ID 4445858. Arbutus focuses on developing treatments for chronic hepatitis B and coronaviruses.
Arbutus Biopharma (NASDAQ: ABUS), in collaboration with X-Chem and Proteros, has announced a new agreement to discover oral inhibitors targeting the SARS-CoV-2 nsp5 main protease. This partnership aims to speed up the development of treatments for COVID-19 and future coronaviruses. The collaboration leverages Arbutus's antiviral expertise, X-Chem's DNA-encoded library technology, and Proteros' structural biology capabilities. The financial terms of the agreement remain undisclosed, and the goal is to identify unique antiviral therapies that can lead to oral treatments for coronavirus-related diseases.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has received regulatory approval to start a Phase 1a/1b clinical trial for AB-836, its oral capsid inhibitor targeting chronic hepatitis B virus (HBV) infection. The trial initiation is a significant milestone toward potential combinations with AB-729. Pre-clinical studies suggest that AB-836 may offer improved efficacy and safety compared to earlier capsid inhibitors. This candidate has demonstrated activity against resistant HBV variants, highlighting its potential in a large patient population suffering from chronic HBV, estimated at over 250 million globally.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported robust clinical progress for its lead compound, AB-729, an RNAi agent targeting chronic hepatitis B (HBV). The latest data show significant declines in hepatitis B surface antigen (HBsAg) levels, with favorable safety profiles. Upcoming clinical trials include Phase 2 combinations of AB-729 with core inhibitors. Financially, the company ended 2020 with $123.3 million in cash, a reduction in net loss to $75.9 million, and reduced expenses, projecting a cash runway through Q3 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation focuses on the company's efforts to develop a cure for chronic hepatitis B virus (HBV) infections and therapies for coronaviruses, including COVID-19. Interested parties can access the webcast on Arbutus' website starting at 7:00 am (EST) on March 9, with an archived replay available afterward.
Assembly Biosciences and Arbutus Biopharma have initiated a Phase 2 clinical trial to evaluate the combination of Assembly's vebicorvir (VBR) and Arbutus’ AB-729 with standard NrtI therapy for chronic hepatitis B Virus (HBV) infection. The trial aims to enroll around 60 patients and assess the safety and antiviral activity of the treatments over 48 weeks. Both companies believe this multi-drug approach is essential for achieving a durable functional cure for HBV, addressing the significant unmet need in HBV therapies.
Arbutus Biopharma Corporation (Nasdaq: ABUS) will announce its fourth quarter and year-end 2020 financial results on March 4, 2021. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. The company focuses on developing a cure for chronic hepatitis B virus (HBV) and therapies for coronaviruses, including COVID-19. Live access to the conference call will be available via the company's investor website.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its 2021 objectives and financial update, focusing on its hepatitis B research and development pipeline. The lead asset, AB-729, shows promising Phase 1a/b clinical trial results, with plans for Phase 2a trials this year. Additionally, AB-836 is set to enter Phase 1a/1b trials. As of December 31, 2020, the company reported approximately $123.3 million in cash and anticipates a net cash burn of $70-75 million in 2021, extending its cash runway to mid-2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is participating in the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The virtual fireside chat will feature key executives, including President and CEO William Collier and Chief Scientific Officer Dr. Michael Sofia. The chat will be accessible via the company's website starting at 6:00 am EST on January 11, 2021. Arbutus focuses on developing treatments for chronic hepatitis B virus (HBV) and coronaviruses like COVID-19, with multiple drug candidates in progress.
